A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults who have Left Ventricular Systolic Dysfunction following Myocardial Infarction.

Trial Profile

A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults who have Left Ventricular Systolic Dysfunction following Myocardial Infarction.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs NP 202 (Primary)
  • Indications Left ventricular dysfunction; Myocardial infarction
  • Focus Therapeutic Use
  • Sponsors Armaron Biosciences
  • Most Recent Events

    • 26 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Feb 2018.
    • 26 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top